FSD Pharma announces share consolidation, rebranding as Quantum BioPharma Ltd., and a new private placement to strengthen market position and meet Nasdaq requirements.
FSD Pharma shares are trading higher Friday after the company provided an update on its investment in Celly Nutrition. Here's a look at what's going on:
HUGE Biopharma Australia, a subsidiary of biopharma company FSD Pharma Inc. (NASDAQHUGE), has agreed with clinical research organization Ingenu CRO to conduct a cross-over clinical study on a proprietary licensed beverage targeting alcohol metabolization in intoxicated states.
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also contains a mandate to fund clinical trials with psychedelics for active service members.
Among a biotech space bursting with innovation, one company stands out as it is developing two assets at once: a ready-for-market drink that can take someone from a drinking state to mental and physical composure in record time and a potential breakthrough therapy for Multiple Sclerosis. Meet FSD Pharma (NASDAQ:
